论文部分内容阅读
目的:罗格列酮(RGZ)联合二甲双胍治疗初诊2型糖尿病(T2DM)的临床疗效和安全性。方法:40例初诊2型糖尿病联用罗格列酮和二甲双胍进行12周的治疗,测定治疗前后空腹血糖(FBG)、餐后2小时血糖(PPG)、糖化血红蛋白(HbA1c)、胰岛素、C-肽、甘油三脂、体重指数(BMI),胰岛素抵抗指数(IR)、血常规、肝、肾功能等。结果:治疗前后对照,空腹及餐后血糖、胰岛素、甘油三脂I、RI降低,具有显著差异性(P<0.001),体重指数变化不大(P>0.05),未发生肝肾功能损害。结论:罗格列酮联合二甲双胍治疗2型糖尿病,明显改善胰岛素抵抗,降糖疗效确切。
Objective: The clinical efficacy and safety of rosiglitazone (RGZ) and metformin in the treatment of newly diagnosed type 2 diabetes mellitus (T2DM). Methods: Forty patients with newly diagnosed type 2 diabetes were treated with rosiglitazone and metformin for 12 weeks. FBG, PPG, HbA1c, Peptide, triglyceride, body mass index (BMI), insulin resistance index (IR), blood, liver, kidney function and the like. Results: Before and after treatment, the fasting and postprandial blood glucose, insulin, triglyceride I and RI were significantly decreased (P <0.001). The body mass index did not change much (P> 0.05), and liver and kidney dysfunction did not occur. Conclusion: Rosiglitazone combined with metformin in treatment of type 2 diabetes mellitus, significantly improve insulin resistance, hypoglycemic effect is exact.